Everolimus: all 667 studies that test it

Page 3 of 7. Open to participants first (47), then studies with results posted, then the rest; newest registration first within each.

• Cisplatin, Paclitaxel, and Everolimus in Treating Patients With Metastatic Breast CancerCompletedNCT01031446Phase 1/2Results posted
• Study of RAD001 and Bevacizumab in Recurrent Ovarian, Peritoneal, and Fallopian Tube CancerCompletedNCT01031381Phase 2Results posted
• Non-inferiority Study of Safety and Efficacy of Everolimus With Low Dose Tacrolimus to Mycophenolate Mofetil With Standard Dose Tacrolimus in Kidney Transplant RecipientsCompletedNCT01025817Phase 3Results posted
• Everolimus (RAD001) for the Treatment of Malignant Pleural Mesothelioma With Merlin/NF2 Loss as a Biomarker to Predict SensitivityCompletedNCT01024946Phase 2Results posted
• Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine- or Vinorelbine- or Vinblastine-based Treatment.CompletedNCT01022996Phase 2Results posted
• Everolimus in de Novo Heart Transplant RecipientsCompletedNCT01017029Phase 4Results posted
• Study of Everolimus With Paclitaxel and Carboplatin in Patients With Metastatic MelanomaCompletedNCT01014351Phase 2Results posted
• RAD001 in Combination With Cetuximab and Cisplatin in Recurrent and Metastatic SCCHNTerminatedNCT01009346Phase 1/2Results posted
• Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast CancerCompletedNCT01007942Phase 3Results posted
• Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach CancerCompletedNCT00985192Phase 2Results posted
• Epigenetic Modulation in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)TerminatedNCT00978432Phase 2Results posted
• Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant MelanomaCompletedNCT00976573Phase 2Results posted
• Everolimus (RAD001) in Primary Therapy of Waldenstrom's MacroglobulinemiaCompletedNCT00976248Phase 2Results posted
• Trial of the Combination of Bevacizumab and Everolimus in Patients With Refractory, Progressive Intracranial MeningiomaTerminatedNCT00972335Phase 2Results posted
• RAD001 Study in Treatment of Relapsed or Refractory Acute Lymphocytic LeukemiaCompletedNCT00968253Phase 1/2Results posted
• Panobinostat (LBH589) Plus Everolimus (RAD001) in Patients With Relapsed and Refractory LymphomaCompletedNCT00967044Phase 1/2Results posted
• Efficacy and Safety of Everolimus+EC-MPS After Early CNI Elimination vs EC-MPS +Tacrolimus in Renal Transplant RecipientsCompletedNCT00965094Phase 4Results posted
• Study to Evaluate the Efficacy, Safety and Tolerability of Everolimus in de Novo Renal Transplant Recipients Participating in the Eurotransplant Senior ProgramTerminatedNCT00956293Phase 4Results posted
• Trial of RAD001 and Erlotinib With Recurrent Head and Neck Squamous Cell CarcinomaCompletedNCT00942734Phase 2Results posted
• RAD001 for Patients With Radioiodine Refractory Thyroid CancerCompletedNCT00936858Phase 2Results posted
• Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown PrimaryCompletedNCT00936702Phase 2Results posted
• Everolimus and Alemtuzumab in Treating Patients With Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaCompletedNCT00935792Phase 1/2Results posted
• Phase I/II Study of Weekly Abraxane and RAD001 in Women With Locally Adv. or Metastatic Breast CaTerminatedNCT00934895Phase 1/2Results posted
• Cisplatin and Paclitaxel With or Without Everolimus in Treating Patients With Stage II or Stage III Breast CancerCompletedNCT00930930Phase 2Results posted
• Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin LymphomaCompletedNCT00918333Phase 1/2Results posted
• Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast CancerCompletedNCT00915603Phase 2Results posted
• Phase II Trial of EVEROLIMUS ± Trastuzumab in Hormone-Refractory Metastatic Breast CancerCompletedNCT00912340Phase 2Results posted
• Efficacy and Safety Comparison of RAD001 Versus Sunitinib in the First-line and Second-line Treatment of Patients With Metastatic Renal Cell CarcinomaCompletedNCT00903175Phase 2Results posted
• Bevacizumab With or Without Everolimus in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal CancerCompletedNCT00886691Phase 2Results posted
• Safety and Efficacy of RAD001 (Everolimus) Monotherapy Plus Best Supportive Care in Patients With Advanced Gastric Cancer (AGC)CompletedNCT00879333Phase 3Results posted
• Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast CancerCompletedNCT00876395Phase 3Results posted
• Everolimus Plus Rituximab for Relapsed/Refractory Diffuse Large B Cell LymphomaCompletedNCT00869999Phase 2Results posted
• Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or AnastrozoleCompletedNCT00863655Phase 3Results posted
• The Efficacy of Oral Everolimus in Patients With Neovascular Age-related Macular DegenerationTerminatedNCT00857259Phase 2Results posted
• RAD001 and Erlotinib in Patients With Neuroendocrine TumorsTerminatedNCT00843531Phase 2Results posted
• Everolimus (RAD001) For Advanced Renal Cell Carcinoma (RCC) Before Kidney RemovalTerminatedNCT00831480Phase 2Results posted
• Trial of RAD001 in Triple Negative Metastatic Breast CancerTerminatedNCT00827567Phase 2Results posted
• Biomarker Trial of Everolimus in Patients With Advanced Renal Cell CarcinomaCompletedNCT00827359Phase 2Results posted
• Everolimus in Treating Patients With Recurrent Low-Grade GliomaCompletedNCT00823459Phase 2Results posted
• Bicalutamide With or Without Everolimus in Treating Patients With Recurrent or Metastatic Prostate CancerCompletedNCT00814788Phase 2Results posted
• Pilot Study of mTOR Inhibitor Therapy in Peutz-Jeghers SyndromeTerminatedNCT00811590Phase 2Results posted
• RAD001(Everolimus) in Treating Patients With Myelodysplastic SyndromesTerminatedNCT00809185Phase 2Results posted
• RT, Temozolomide, and Bevacizumab Followed by Bevacizumab/Everolimus in First-line Treatment of GBMCompletedNCT00805961Phase 2Results posted
• Everolimus (RAD001) in Metastatic Transitional Cell Carcinoma of the UrotheliumCompletedNCT00805129Phase 2Results posted
• Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM)CompletedNCT00790400Phase 3Results posted
• Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapyCompletedNCT00790036Phase 3Results posted
• Efficacy and Safety of Everolimus (RAD001) in Patients of All Ages With Subependymal Giant Cell Astrocytoma Associated With Tuberous Sclerosis Complex (TSC)(EXIST-1)CompletedNCT00789828Phase 3Results posted
• Everolimus (RAD001) for Children With Chemotherapy-Refractory Progressive or Recurrent Low-Grade GliomasCompletedNCT00782626Phase 2Results posted
• S0722: Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By SurgeryCompletedNCT00770120Phase 2Results posted
• Treatment of Patients With RAD001 With Progressive SarcomaCompletedNCT00767819Phase 2Results posted
• RAD001 (Everolimus) Salvage Monotherapy in Advanced Gastric Cancer (AGC) Who Failed Standard First-line TreatmentCompletedNCT00729482Phase 2Results posted
• Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney CancerCompletedNCT00719264Phase 2Results posted
• Safety and Efficacy of RAD001 in Participants With Mantle Cell Lymphoma Who Are Refractory or Intolerant to Velcade® TherapyCompletedNCT00702052Phase 2Results posted
• RAPTOR: RAD001 as Monotherapy in the Treatment of Advanced Papillary Renal Cell Tumors Program in EuropeCompletedNCT00688753Phase 2Results posted
• RAMSETE: RAD001 in Advanced and Metastatic Silent Neuro-endocrine Tumors in EuropeCompletedNCT00688623Phase 2Results posted
• Concentration Controlled Everolimus With Reduced Dose Cyclosporine Versus Mycophenolate Mofetil With Standard Dose Cyclosporine in de Novo Renal Transplant Adult Recipients Treated With Basiliximab and CorticosteroidsCompletedNCT00658320Phase 3Results posted
• Treatment of Refractory Metastatic Renal Cell Carcinoma With Bevacizumab and RAD001 (Everolimus)TerminatedNCT00651482Phase 2Results posted
• Erlotinib and RAD001 (Everolimus) in Patients With Previously Treated Advanced Pancreatic CancerTerminatedNCT00640978Phase 2Results posted
• Evaluation of Early Conversion to Everolimus From Cyclosporine in de Novo Renal Transplant RecipientsCompletedNCT00634920Phase 4Results posted
• RAD001 and Bicalutamide for Androgen Independent Prostate CancerCompletedNCT00630344Phase 2Results posted
• RAD001 in Patients With Metastatic, Hormone-Refractory Prostate CancerCompletedNCT00629525Phase 2Results posted
• Efficacy and Safety of Concentration-controlled Everolimus to Eliminate or to Reduce Tacrolimus Compared to Tacrolimus in de Novo Liver Transplant RecipientsCompletedNCT00622869Phase 3Results posted
• Avastin (Bevacizumab) and RAD001 (Everolimus) in Advanced Low or Intermediate Grade Neuroendocrine CarcinomaCompletedNCT00607113Phase 2Results posted
• Expanded Cohort for Metastatic Colorectal Cancer (MCRC) Using Bevacizumab + EverolimusCompletedNCT00597506Phase 2Results posted
• RAD001 Plus Bevacizumab in Metastatic MelanomaCompletedNCT00591734Phase 2Results posted
• Efficacy of Everolimus as Inhibitor of Fibrosis Progression in Liver Transplant Patients With Recurrence of Hepatitis C Viral InfectionTerminatedNCT00582738Phase 2Results posted
• RAD001 and Temozolomide in Patients With Advanced Pancreatic Neuroendocrine TumorsCompletedNCT00576680Phase 1/2Results posted
• Study of Combined Fulvestrant and Everolimus in Advanced/Metastatic Breast Cancer After Aromatase Inhibitor FailureCompletedNCT00570921Phase 2Results posted
• Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed GlioblastomaCompletedNCT00553150Phase 1/2Results posted
• Exploratory Study Evaluating Fluorodeoxyglucose - Position Emission Tomography as a Predictive Marker for Therapy With RAD001 in Metastatic Renal Cell CancerCompletedNCT00529802Phase 2Results posted
• Everolimus in Treating Patients With Newly Diagnosed Localized Prostate CancerTerminatedNCT00526591Phase 2Results posted
• Temozolomide and Everolimus in Treating Patients With Stage IV Melanoma That Cannot be Removed by SurgeryCompletedNCT00521001Phase 2Results posted
• RAD001 in Advanced Hepatocellular CarcinomaCompletedNCT00516165Phase 1/2Results posted
• Study Investigating a Standard Regimen in de Novo Kidney Transplant Patients Versus a Calcineurin Inhibitor (CNI)-Free Regimen and a CNI-low Dose RegimenCompletedNCT00514514Phase 3Results posted
• Efficacy and Safety of Everolimus (RAD001) Compared to Placebo in Patients With Advanced Neuroendocrine TumorsCompletedNCT00510068Phase 3Results posted
• Paclitaxel Followed by FEC Versus Paclitaxel and RAD001 Followed by FEC In Women With Breast CancerStatus unknownNCT00499603Phase 2Results posted
• Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple MyelomaCompletedNCT00474929Phase 1/2Results posted
• The Use of RAD001 With Docetaxel in the Treatment of Metastatic, Androgen Independent Prostate CancerCompletedNCT00459186Phase 1/2Results posted
• Dose Escalation Followed by Study of RAD001 in Combination With Trastuzumab in HER2-Positive Metastatic Breast CancerCompletedNCT00458237Phase 1/2Results posted
• Everolimus (RAD001) as Therapy for Patients With Systemic MastocytosisCompletedNCT00449748Phase 2Results posted
• Everolimus in Treating Patients With Lymphoma That Has Relapsed or Not Responded to Previous TreatmentCompletedNCT00436618Phase 2Results posted
• Efficacy and Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast CancerCompletedNCT00426556Phase 1Results posted
• Efficacy and Safety of Everolimus in Combination With Cyclosporine Microemulsion Versus Everolimus in Combination With Enteric-coated Mycophenolate Sodium (EC-MPS), in Adult Renal Transplant Patients in Maintenance.CompletedNCT00425308Phase 3Results posted
• Efficacy and Safety of Everolimus in Patients With Metastatic Colorectal Cancer Who Have Failed Prior Targeted Therapy and ChemotherapyCompletedNCT00419159Phase 2Results posted
• Efficacy, Safety and Tolerability of Everolimus in Preventing End-stage Renal Disease in Patients With Autosomal Dominant Polycystic Kidney DiseaseCompletedNCT00414440Phase 4Results posted
• Everolimus and Octreotide in Patients With Advanced Carcinoid TumorCompletedNCT00412061Phase 3Results posted
• Everolimus (RAD001) Therapy of Giant Cell Astrocytoma in Patients With Tuberous Sclerosis ComplexCompletedNCT00411619Phase 1/2Results posted
• RAD001 Plus Best Supportive Care (BSC) Versus BSC Plus Placebo in Patients With Metastatic Carcinoma of the Kidney Which Has Progressed After Treatment With Sorafenib and/or SunitinibCompletedNCT00410124Phase 3Results posted
• RAD001 in Previously Treated Patients With Metastatic Pancreatic CancerCompletedNCT00409292Phase 2Results posted
• Phase I/II Trial of RAD001 Plus Docetaxel in Patients With Metastatic or Recurrent Non-Small Cell Lung CancerTerminatedNCT00406276Phase 1/2Results posted
• Trial of RAD001 in Patients With Operable Non-Small Cell Lung Cancer (NSCLC)CompletedNCT00401778Phase 1Results posted
• Dosing and Effectiveness Study of Sorafenib and RAD001 in the Treatment of Patients With Advanced Kidney CancerCompletedNCT00392821Phase 1/2Results posted
• Everolimus in Treating Patients With Advanced or Metastatic Colorectal Cancer That Did Not Respond to Previous TherapyTerminatedNCT00390364Phase 2Results posted
• Nordic Everolimus (Certican) Trial in Heart and Lung TransplantationCompletedNCT00377962Phase 4Results posted
• Phase II Trial of RAD001 (Everolimus) in Previously Treated Small Cell Lung CancerCompletedNCT00374140Phase 2Results posted
• SOCRATES: Steroid or Cyclosporine Removal After Transplantation Using EverolimusCompletedNCT00371826Phase 4Results posted
• A Twelve-month, Multicenter, Open-label, Randomized Study of the Safety, Tolerability and Efficacy of Everolimus With Basiliximab, Corticosteroids and Two Different Exposure Levels of Tacrolimus in de Novo Renal Transplant RecipientsCompletedNCT00369161Phase 4Results posted
• Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to ChemotherapyCompletedNCT00363051Phase 2Results posted
• Comparison of CNI-based Regimen Versus CNI-free Regimen in Kidney Transplant Recipients.TerminatedNCT00332839Phase 4Results posted
• Everolimus and Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Kidney CancerCompletedNCT00331409Phase 2Results posted

← Everolimus overview